Targeting the TFAM-cGAS-STING axis: a mitochondrial-inflammatory link in the pathogenesis and treatment of diabetic kidney disease
- PMID: 40658146
- DOI: 10.1007/s11255-025-04651-7
Targeting the TFAM-cGAS-STING axis: a mitochondrial-inflammatory link in the pathogenesis and treatment of diabetic kidney disease
Abstract
Diabetic kidney disease (DKD) is one of the common and devastating chronic complications of diabetes, its pathogenesis remains incompletely understood. Emerging evidence suggests that mitochondrial dysfunction plays a crucial role in the onset and progression of DKD. Mitochondrial transcription factor A (TFAM), a key regulator of mitochondrial DNA (mtDNA) expression, is essential for maintaining mitochondrial integrity and function, and is increasingly recognized for its role in modulating inflammatory signaling. This review focuses on the regulatory mechanisms by which TFAM stabilizes mitochondrial function and prevents mtDNA leakage, thereby inhibiting activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. Suppression of this pathway has been shown to alleviate renal inflammation and fibrosis. Given the current lack of curative therapies for DKD, targeting the TFAM-cGAS-STING signaling axis represents a promising novel strategy for both therapeutic intervention and mechanistic research in DKD.
Keywords: Diabetic kidney disease; Inflammation; Mitochondrial dysfunction; TFAM; cGAS–STING pathway.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: Not applicable. Informed consent: Informed consent was obtained from all participants.
Similar articles
-
Crosstalk between oxidative stress, mitochondrial dysfunction, chromosome instability, and the activation of the cGAS-STING/IFN pathway in systemic sclerosis.Ageing Res Rev. 2025 Aug;110:102812. doi: 10.1016/j.arr.2025.102812. Epub 2025 Jun 23. Ageing Res Rev. 2025. PMID: 40562314 Review.
-
Mitochondrial DNA release via the mitochondrial permeability transition pore activates the cGAS-STING pathway, exacerbating inflammation in acute Kawasaki disease.Cell Commun Signal. 2024 Jun 13;22(1):328. doi: 10.1186/s12964-024-01677-9. Cell Commun Signal. 2024. PMID: 38872145 Free PMC article.
-
Activation of the cGAS-sting Pathway Mediated by Nanocomplexes for Tumor Therapy.Curr Pharm Des. 2025;31(20):1604-1618. doi: 10.2174/0113816128339788241221160639. Curr Pharm Des. 2025. PMID: 39819537 Review.
-
cGAS-STING targeting offers novel therapeutic regimen in sepsis-associated organ dysfunction.Cell Biol Toxicol. 2025 Jul 3;41(1):113. doi: 10.1007/s10565-025-10051-5. Cell Biol Toxicol. 2025. PMID: 40608126 Free PMC article. Review.
-
Advances in cGAS-STING Signaling in Fibrosis Diseases: Therapeutic Target in Pathological Scars.J Inflamm Res. 2025 Aug 9;18:10777-10793. doi: 10.2147/JIR.S541656. eCollection 2025. J Inflamm Res. 2025. PMID: 40809466 Free PMC article. Review.
References
-
- Wang X, Deng Z, Wang Y (2025) IgG expressed by renal tubular epithelial cells in epithelial mesenchymal transformation and interstitial fibrosis in diabetic kidney disease. Ren Fail 47(1):2458764. https://doi.org/10.1080/0886022x.2025.2458764 - DOI - PubMed - PMC
-
- Zhou Y, Liu Y, Wu L, Zhang Y, Wen H, Hu J, Huo Z, Ju S, Sheng R (2025) Causal insights into major risk factors for diabetic kidney disease: a comprehensive meta-analysis and Mendelian randomization study. Ren Fail 47(1):2468741. https://doi.org/10.1080/0886022x.2025.2468741 - DOI - PubMed - PMC
-
- Sood A, Sawhney A, Borokhovsky B, Vyas AV, Gupta R (2025) A drug safety evaluation of dapagliflozin for diabetic nephropathies in patients with cardiovascular risk. Expert Opin Drug Saf 24(3):241–250. https://doi.org/10.1080/14740338.2025.2462671 - DOI - PubMed
-
- Association AD (2022) Standards of care in diabetes-2023 abridged for primary care providers. Clin Diabetes 41(1):4–31. https://doi.org/10.2337/cd23-as01 - DOI
-
- Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348(23):2285–2293. https://doi.org/10.1056/NEJMoa021835 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials